Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Lymphoma 9Leukemia, Lymphocytic, Chronic, B-Cell 9Lymphoma, Follicular 8Lymphoma, Mantle-Cell 7Lymphoma, Non-Hodgkin 6Lymphoma, Large B-Cell, Diffuse 4Lymphoma, B-Cell 3Waldenstrom Macroglobulinemia 2Recurrence 2Neoplasms 2Lymphoma, B-Cell, Marginal Zone 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Ovarian Neoplasms 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell 1Leukemia 1Immunoblastic Lymphadenopathy 1Hodgkin Disease 1Hematologic Neoplasms 1Hematologic Diseases 1Fallopian Tube Neoplasms 1Burkitt Lymphoma 1

Interventions

Rituximab 9venetoclax 7ibrutinib 7Cyclophosphamide 7Mycophenolic Acid 5fludarabine phosphate 4Whole-Body Irradiation 4Sirolimus 4zanubrutinib 3pirtobrutinib 3Peripheral Blood Stem Cell Transplantation 3Dexamethasone 3Cyclosporine 3ixazomib 2fludarabine 2carfilzomib 2acalabrutinib 2Tacrolimus 2Melphalan 2Etoposide 2Cyclosporins 2Calcium Dobesilate 2CT-P10 2Busulfan 2Bendamustine Hydrochloride 2talquetamab 1pembrolizumab 1loncastuximab tesirine 1brexucabtagene autoleucel 1Vincristine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Waldenstrom Macroglobulinemia × Bendamustine Hydrochloride × 90 days × Clear all
NCT06561347 2026-03-31

ZEBRA

Massachusetts General Hospital

Phase 2 Recruiting
55 enrolled
Lymphoid

Waldenstrom Macroglobulinemia

NCT01479842 2026-03-23

Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma

Ohio State University Comprehensive Cancer Center

Phase 1 Active not recruiting
48 enrolled
Lymphoid

Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡